1 Prediction of 90 Y‐Radioembolization Outcome from Pre‐therapeutic Factors with Random Survival Forests Michael Ingrisch 1,* , Franziska Schöppe 1 , Karolin Paprottka 1 , Matthias Fabritius 1 , Frederik F. Strobl 1 , Enrico De Toni 2 , Harun Ilhan 3 , Andrei Todica 3 , Marlies Michl 4 , Philipp Marius Paprottka 1 1 Department of Radiology University Hospital Munich, Ludwig‐Maximilians‐University Munich 2 Department of Internal Medicine II University Hospital Munich, Ludwig‐Maximilians‐University Munich 3 Department of Nuclear Medicine University Hospital Munich, Ludwig‐Maximilians‐University Munich 4 Department of Internal Medicine III University Hospital Munich, Ludwig‐Maximilians‐University Munich * Corresponding author: Dr. Michael Ingrisch Department of Radiology University Hospital Munich, Ludwig‐Maximilians‐University Munich Marchioninistr. 15 81377 München Tel. +49 89 4400 74624 E‐Mail [email protected]ORCID 0000‐0003‐0268‐9078 Word count: 3297 Running title: Prediction of radioembolization outcome Journal of Nuclear Medicine, published on November 16, 2017 as doi:10.2967/jnumed.117.200758 by on August 14, 2020. For personal use only. jnm.snmjournals.org Downloaded from
19
Embed
Prediction of 90Y-Radioembolization Outcome from Pre ...jnm.snmjournals.org/content/early/2017/11/15/... · Radioembolization with 90Yttrium‐loaded resin microspheres is an established
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Predictionof90Y‐RadioembolizationOutcomefromPre‐therapeuticFactorswithRandomSurvivalForestsMichael Ingrisch1,*, Franziska Schöppe1, Karolin Paprottka1, Matthias Fabritius1, Frederik F. Strobl1, Enrico
De Toni2, Harun Ilhan3, Andrei Todica3, Marlies Michl4, Philipp Marius Paprottka1
1Department of Radiology University Hospital Munich, Ludwig‐Maximilians‐University Munich 2Department of Internal Medicine II University Hospital Munich, Ludwig‐Maximilians‐University Munich
3Department of Nuclear Medicine University Hospital Munich, Ludwig‐Maximilians‐University Munich 4Department of Internal Medicine III University Hospital Munich, Ludwig‐Maximilians‐University Munich *Corresponding author: Dr. Michael Ingrisch Department of Radiology University Hospital Munich, Ludwig‐Maximilians‐University Munich Marchioninistr. 15 81377 München Tel. +49 89 4400 74624 E‐Mail [email protected] ORCID 0000‐0003‐0268‐9078
Word count: 3297
Running title: Prediction of radioembolization outcome
Journal of Nuclear Medicine, published on November 16, 2017 as doi:10.2967/jnumed.117.200758by on August 14, 2020. For personal use only. jnm.snmjournals.org Downloaded from
1. Malfertheiner P, Verslype C, Kolligs FT, et al. The effectiveness of selective internal radiation therapy in challenging cases of liver‐predominant unresectable hepatocellular carcinoma. Future Oncol Lond Engl. 2014;10:17‐27.
2. Kloeckner R, Ruckes C, Kronfeld K, et al. Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. Trials. 2014;15:311.
3. Jakobs TF, Paprottka KJ, Raeßler F, et al. Robust evidence for long‐term survival with (90)Y radioembolization in chemorefractory liver‐predominant metastatic colorectal cancer. Eur Radiol. 2017;27:113‐119.
4. Sommer WH, Ceelen F, García‐Albéniz X, et al. Defining predictors for long progression‐free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013;23:3094‐3103.
5. Paprottka PM, Hoffmann R‐T, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium‐90 microspheres. Cardiovasc Intervent Radiol. 2012;35:334‐342.
6. Fendler WP, Lechner H, Todica A, et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: A large single‐center experience in 81 patients. J Nucl Med. 2016;57:517‐523.
7. Damm R, Seidensticker R, Ulrich G, et al. Y90 Radioembolization in chemo‐refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer. 2016;16:509.
8. Fendler WP, Ilhan H, Paprottka PM, et al. Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. Eur Radiol. 2015;25:2693‐2700.
9. Paprottka KJ, Schoeppe F, Ingrisch M, et al. Pre‐therapeutic factors for predicting survival after radioembolization: a single‐center experience in 389 patients. Eur J Nucl Med Mol Imaging. 2017;44:1185‐1193
10. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random Survival Forests. Ann Appl Stat. 2008;2:841‐860.
11. Hsich E, Gorodeski EZ, Blackstone EH, Ishwaran H, Lauer MS. Identifying important risk factors for survival in patient with systolic heart failure using random survival forests. Circ Cardiovasc Qual Outcomes. 2011;4:39‐45.
12. Ingrisch M, Schneider MJ, Nörenberg D, et al. Radiomic analysis reveals prognostic information in T1‐weighted baseline magnetic resonance imaging in patients with glioblastoma. Invest Radiol. 2017;52:360‐366.
by on August 14, 2020. For personal use only. jnm.snmjournals.org Downloaded from
13. Ishwaran H, Kogalur UB, Chen X, Minn AJ. Random survival forests for high‐dimensional data. Stat Anal Data Min. 2011;4:115‐132.
14. Ishwaran H, Kogalur UB. Random forests for survival, regression and classification (RF‐SRC) [Internet]. manual; 2016. Accessed 6/14/2016. Available from: https://cran.r‐project.org/package=randomForestSRC
15. Mendel B, Rudney H. Studies on cholinesterase: 1. Cholinesterase and pseudo‐cholinesterase. Biochem J. 1943;37:59‐63.
16. Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLOS ONE. 2012;7:e51862.
17. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2015;278:563‐577.
18. Kickingereder P, Götz M, Muschelli J, et al. Large‐scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti‐angiogenic treatment response. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:5765‐5771.
by on August 14, 2020. For personal use only. jnm.snmjournals.org Downloaded from
Doi: 10.2967/jnumed.117.200758Published online: November 16, 2017.J Nucl Med. Harun Ilhan, Andrei Todica, Marlies Michl and Philipp PaprottkaMichael Ingrisch, Franziska Schöppe, Karolin Johanna Paprottka, Matthias Fabritius, Frederik F. Strobl, Enrico de Toni, Random Survival Forests
Y-Radioembolization Outcome from Pre-therapeutic Factors with90Prediction of
http://jnm.snmjournals.org/content/early/2017/11/15/jnumed.117.200758This article and updated information are available at:
Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/misc/permission.xhtmlInformation about reproducing figures, tables, or other portions of this article can be found online at:
and the final, published version.proofreading, and author review. This process may lead to differences between the accepted version of the manuscript
ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting,JNMcopyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the
. They have not beenJNM ahead of print articles have been peer reviewed and accepted for publication in JNM
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)1850 Samuel Morse Drive, Reston, VA 20190.SNMMI | Society of Nuclear Medicine and Molecular Imaging
is published monthly.The Journal of Nuclear Medicine